Apollomics (APLM) Short term Debt (2023 - 2024)
Apollomics (APLM) posted quarterly Short term Debt of $3.5 million for Q2 2024, down 17.19% on a QoQ basis from $4.2 million in Q4 2023.
Apollomics (APLM) Short term Debt (2023 - 2024) Analysis & Trends
Apollomics (APLM) has reported Short term Debt for 2 consecutive years, with $3.5 million the latest figure, recorded in Q2 2024.
- Quarterly Short term Debt changed N/A year-over-year to $3.5 million in Q2 2024, while the trailing twelve-month figure through Jun 2024 was $3.5 million (changed N/A YoY) and the FY2023 annual result came in at $4.2 million, changed N/A from the prior year.
- Short term Debt retreated to $3.5 million in Q2 2024 per APLM's latest filing, from $4.2 million in the prior quarter.
- Over the last five years, Short term Debt for APLM reached as high as $4.2 million in Q4 2023 and fell as low as $3.5 million in Q2 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - |
| 10 | Apollomics | 2.66 Bn | 2.66 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2024 | 3.51 Mn |
| Dec 31, 2023 | 4.24 Mn |